Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDRASE vs QUINIDEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Primary dysmenorrhea
Conversion and prevention of atrial fibrillation/flutter,Maintenance of sinus rhythm after cardioversion,Treatment of ventricular arrhythmias (off-label)
Adult: 100 mg orally twice daily.
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
Hepatic metabolism primarily via CYP2C9, with minor contributions from CYP3A4 and CYP2C8. Metabolites are inactive and excreted renally.
Primarily hepatic via CYP3A4 (major) and CYP2C9 (minor) to active metabolites (3-hydroxyquinidine, quinidine-N-oxide); also renal excretion of unchanged drug (20%).
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (10-20%); biliary/fecal elimination accounts for 10-15%.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
80-90% bound to plasma proteins: primarily albumin and alpha-1-acid glycoprotein.
0.2-0.3 L/kg, indicating limited distribution into tissues, consistent with high plasma protein binding.
2-4 L/kg; extensive tissue distribution with high affinity for myocardium (tissue-to-plasma ratio >10).
Oral bioavailability is 80-90% with modest first-pass metabolism; intravenous administration yields 100% bioavailability.
70-80% for immediate-release oral; 50-70% for sustained-release formulations due to first-pass metabolism; absorption reduced by food.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 100 mg once daily. GFR 15-29 m L/min: 50 mg once daily. GFR <15 m L/min: Not recommended.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours. Cr Cl 10-29 m L/min: administer 50% of normal dose every 8 hours. Cr Cl <10 m L/min: administer 50% of normal dose every 12 hours.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose by 50%; monitor levels. Child-Pugh class C: contraindicated or use with extreme caution; reduce dose by 75% with therapeutic drug monitoring.
Children ≥1 year: 2 mg/kg orally twice daily, up to a maximum of 100 mg/dose.
Oral: 15-60 mg/kg/day in 4-5 divided doses; maximum single dose 600 mg. For chronic suppression: start 30 mg/kg/day in 4-5 divided doses.
Initial dose of 50 mg once daily; may increase to 100 mg once daily based on tolerability.
Start at lower end of dosing range (200 mg every 8 hours) due to decreased hepatic and renal function; adjust based on plasma levels and QT interval monitoring.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Increased mortality in treatment of non-life-threatening ventricular arrhythmias; proarrhythmic effects (torsades de pointes).
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, anaphylactoid reactions, serious skin reactions, hematologic toxicity, hepatic impairment, asthma exacerbation, and use in pregnancy (avoid in later stages).
Proarrhythmia (torsades de pointes), hepatotoxicity, cinchonism, hypersensitivity reactions, worsening of heart failure, digitalis toxicity, incomplete AV block, electrolyte disturbances.
Hypersensitivity to CARDRASE or any NSAID; history of asthma, urticaria, or allergic-type reactions after aspirin or NSAIDs; perioperative pain in CABG surgery; advanced renal disease; severe hepatic impairment; active peptic ulcer or GI bleeding; third trimester of pregnancy; patients with known sulfonamide allergy (if applicable).
Hypersensitivity to quinidine or cinchona alkaloids, complete AV block or severe intraventricular conduction defects, myasthenia gravis, history of thrombocytopenia with quinidine, concurrent use with drugs that prolong QT interval (unless absolutely necessary).
Avoid high-sodium foods to reduce fluid retention. Limit intake of potassium-rich foods if hyperkalemia is a risk. Grapefruit juice may increase drug levels; avoid concurrent use.
Grapefruit juice increases quinidine bioavailability and serum levels, raising toxicity risk. Avoid grapefruit and grapefruit juice. Alkaline foods (e.g., antacids, milk) may increase quinidine absorption. High-sodium diet may enhance potassium loss and worsen arrhythmias. Avoid excessive caffeine or stimulants.
First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third trimester: Risk of neonatal hypoglycemia, hypotonia, and respiratory depression with maternal use near term.
First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal QT prolongation, neonatal thrombocytopenia, and tachycardia. Fetal distress may occur. Avoid if alternative exists, but if needed, monitor fetal ECG and heart rate.
Limited data; drug is excreted in breast milk. M/P ratio unknown. Avoid breastfeeding during therapy due to potential adverse effects in the infant.
Quinidine is excreted into breast milk. M/P ratio reported as 0.57–0.78. Amount is low, but monitor infant for arrhythmias, bruising, and bleeding. Generally considered compatible with breastfeeding if maternal monitoring is done.
Increased renal clearance during pregnancy may require 20-30% dose escalation in second and third trimesters. Monitor therapeutic drug levels to maintain efficacy. Consider dose reduction postpartum.
Increased volume of distribution may require dose increases. Protein binding decreases, potentially lowering total drug concentrations. Monitor free drug levels if possible. adjust dose based on therapeutic drug monitoring and clinical response. Close monitoring recommended.
CARDRASE (carbonic anhydrase inhibitor) may cause metabolic acidosis; monitor serum bicarbonate. Contraindicated in cirrhosis due to risk of hepatic encephalopathy. Can cause hypokalemia; check electrolytes. Adjust dose in renal impairment (Cr Cl <30 m L/min).
Quinidine (as Quinidex) is a class Ia antiarrhythmic; monitor QRS and QT intervals due to risk of torsades de pointes. It also has anticholinergic properties, causing diarrhea in up to 50% of patients, which can be dose-limiting. Drug interactions are critical: quinidine inhibits CYP2D6, increasing levels of digoxin, warfarin, and many beta-blockers. Consider checking serum quinidine levels (therapeutic: 2-6 mcg/m L) and ECG if initiating or adjusting dose.
Take with food to reduce gastrointestinal upset.,Drink plenty of fluids to prevent kidney stones.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report unexplained bruising or bleeding, as it may indicate thrombocytopenia.,Do not drive or operate machinery until you know how this medication affects you, as dizziness or drowsiness can occur.
Take exactly as prescribed; do not double dose if missed.,Avoid grapefruit juice as it can increase quinidine levels and toxicity.,Report new or worsening palpitations, dizziness, syncope, or irregular heartbeat immediately.,May cause diarrhea; contact your prescriber if diarrhea becomes severe or persistent.,Quinidine can cause blurred vision, tinnitus, or headache; report these to your doctor.,Avoid over-the-counter medications without consulting your doctor (especially antacids, antihistamines, and cold remedies).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDRASE vs QUINIDEX, answered by our medical review team.
CARDRASE is a Antiarrhythmic Agent that works by CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. QUINIDEX is a Antiarrhythmic Agent that works by Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDRASE and QUINIDEX depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDRASE is: Adult: 100 mg orally twice daily.. The standard adult dose of QUINIDEX is: Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDRASE and QUINIDEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDRASE is classified as Category C. First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third t. QUINIDEX is classified as Category C. First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal Q. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.